Solesence vs cbdMD
SLSN and YCBD side by side, both in soap, detergents, and cleaning preparations; perfumes, cosmetics, and other toilet preparations. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SLSN and YCBD compare
Solesence is the larger company, worth 26 times as much as cbdMD ($107M against $4.2M).
cbdMD grew revenue faster over the last twelve months (10.0% versus −2.0% for Solesence).
Solesence keeps more of each dollar of sales as profit, with a net margin of 4.5% compared with −13.8% at cbdMD.
Solesence scores higher on the StockData Score (17 against 10 for cbdMD), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SLSN | YCBD |
|---|---|---|
| Size and price | ||
| Market cap | $107M | $4.2M |
| Share price | $1.52 | $0.374 |
| Change, 1 year | −21.6% | −51.7% |
| Change, 5 years | −62.9% | −99.9% |
| Beta (5Y) | 1.46 | 0.61 |
| Employees | 115 | 42 |
| StockData Score | ||
| Total score | 17 (better) | 10 |
| Valuation score | 4 (better) | 3 |
| Growth score | 3 (better) | 1 |
| Performance score | 5 (better) | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 38.0× | – |
| P/S | 1.8× | 0.2× (better) |
| P/B | 6.4× | 0.5× (better) |
| EV/EBITDA | 21.9× | – |
| FCF yield | – | −57.5% |
| Fair value | $1.96 | $2.22 |
| Margin of safety | 22.6% | 83.1% (better) |
| Growth | ||
| Revenue growth (TTM) | −2.0% | 10.0% (better) |
| Revenue growth, 5Y average | 29.4% (better) | −14.5% |
| Net income growth (TTM) | 365% | – |
| EPS growth (TTM) | 300% | – |
| EPS growth, 5Y average | 5.9% | – |
| Profitability | ||
| Gross margin | 31.7% | 57.7% (better) |
| Operating margin | 6.0% (better) | −13.9% |
| Net margin | 4.5% (better) | −13.8% |
| FCF margin | – | −11.5% |
| Return on equity | 18.2% (better) | −40.3% |
| Return on invested capital | 20.4% (better) | −41.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.73 | 2.50 (better) |
| Altman Z-score | 1.09 (better) | −17.57 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.06% | – |
| Shareholder yield | −0.06% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 4.5% | 8.2% |
| Held by insiders | 75.2% | 34.6% |
| Insider net buying, 12 months | $4.8K (better) | −$1.3M |
| Short interest, % of float | 2.1% | 6.6% |
Go deeper
- SLSN stock overview
- SLSN income statement
- SLSN valuation and score
- YCBD stock overview
- YCBD income statement
- YCBD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.